ag-Ip-news

The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization
Arabic
Advanced Search
Mailing List Sign Up
Enter your e-mail address to receive daily headlines.

Unsubscribe
Click here for World Law news from NewsNow.co.uk
WAP Service


AGIPNEWS7609

29/9/2009 14:34 GMT
ag-IP-news
MDRNA Announces Patent Allowance

BOTHELL, WA - MDRNA Inc., a leading RNAi-based drug discovery and development company, announced in a Tuesday press release that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application US 11/624,630 covering an siRNA directed against a junctional adhesion molecule-1 (JAM-1) gene.

The siRNA of the allowed claim has a broad array of potential applications, most notably as a therapeutic for the treatment of certain cancers, thrombosis, atherosclerosis, strokes, and hypertension; and enhances the delivery of drugs across the skin and the blood-brain barrier.

JAM-1 is a tight junction protein that plays a key role in maintaining epithelial and endothelial barrier functions, leukocyte transmigration and platelet adhesion and also functions as a pro-inflammatory molecule.

"This allowance validates our patent strategy for our gene target portfolio, and reinforces our belief that we will obtain patent protection for our extensive library of siRNAs directed against more than 140 therapeutic gene targets," MDRNA President and CEO J. Michael French said.

"As our scientific team develops more novel RNAi technologies, we expect to expand and strengthen our IP estate," French added.

Small interfering RNA (siRNA), sometimes known as short interfering RNA, is a class of double-stranded RNA molecules that play a variety of roles in biology. siRNA is involved in the RNA interference pathway, where it interferes with the expression of a specific gene.

A Notice of Allowance confirms the substantive examination of a patent application and will result in a final issuance of a US patent after an administrative process is completed.

MDRNA has a broad Intellectual Property estate that encompasses four key RNAi technology platforms: siRNA constructs, chemistry, nucleic acid delivery, and gene targets.


Related Articles
Alnylam Receives Notice of Allowance from USPTO
China IP Offices Close for Spring Festival Holiday
Under-Secretary of Commerce Announces Obama’s FY 2011 USPTO Budget Request
Silicon Laboratories Asserts Intellectual Property Rights
WIPO Pledges Support for Viet Nam
INTA and Union Advocate for Resources to Promote IP Protection
Intellectual Property Will Be Protected, Says Viet Nam President
WiLAN Initiates Fraud and V-Chip Patent Litigation Against LG
MOSAID and Samsung Reach Comprehensive Agreement
MDRNA Reports Potent Anti-Tumor Activity

Top
Go

Home | About Us | How to Use Our Services | Links | Download Our News Ticker | FAQ | What is IP? | Contact Us
Copyright © 2008 ag-IP-news All Rights Reserved
Disclaimer   Terms of Use    Privacy Policy